2/26
08:03 am
rxrx
Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
2/26
06:23 am
rxrx
Rating for RXRX
Low
Report
Rating for RXRX
2/26
06:23 am
rxrx
Rating for RXRX
Low
Report
Rating for RXRX
2/25
03:58 pm
rxrx
Recursion Pharmaceuticals (RXRX) had its "neutral" rating reaffirmed by Bank of America Corporation.
Low
Report
Recursion Pharmaceuticals (RXRX) had its "neutral" rating reaffirmed by Bank of America Corporation.
12/17
08:45 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
12/17
08:29 am
rxrx
Rating for RXRX
Medium
Report
Rating for RXRX
12/17
04:46 am
rxrx
Recursion Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
Medium
Report
Recursion Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan